We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.8B
AUM Growth
+$97.9M
Cap. Flow
-$10.3M
Cap. Flow %
-0.37%
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.7M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.5M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$13.3M
5
JNJ icon
Johnson & Johnson
JNJ
+$11.2M

Top Sells

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$23.6M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$12.8M
3
BIIB icon
Biogen
BIIB
+$11.9M
4
AMGN icon
Amgen
AMGN
+$11.4M
5
AKRX
Akorn Inc
AKRX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 93.03%
2 Real Estate 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$44B
$30.4M 1.09%
124,781
– –
PFE icon
27
Pfizer
PFE
$142B
$28.9M 1.03%
853,832
– –
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.64B
$24.3M 0.87%
536,600
+25,000
+5% +$999K
COR icon
29
Cencora
COR
$60.7B
$23.8M 0.85%
288,187
+33,300
+13% +$2.83M
CNC icon
30
Centene
CNC
$30.1B
$22.3M 0.8%
460,316
+75,116
+20% +$3.23M
MCK icon
31
McKesson
MCK
$101B
$21.9M 0.78%
142,800
– –
IDXX icon
32
Idexx Laboratories
IDXX
$44.1B
$20.6M 0.74%
132,352
– –
XBI icon
33
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$19.6M 0.7%
226,460
– –
CI icon
34
Cigna
CI
$76.1B
$18.7M 0.67%
100,002
+16,102
+19% +$2.87M
NVRO
35
DELISTED
NEVRO CORP.
NVRO
$17.7M 0.63%
194,621
– –
PVLA
36
Palvella Therapeutics
PVLA
$2.15B
$16.3M 0.58%
35,470
– –
AZN icon
37
AstraZeneca
AZN
$266B
$15M 0.54%
221,300
-54,000
-20% -$3.41M
OHI icon
38
Omega Healthcare
OHI
$15B
$14.6M 0.52%
458,616
– –
GSK icon
39
GSK
GSK
$104B
$14.6M 0.52%
287,200
– –
CRL icon
40
Charles River Laboratories
CRL
$11.3B
$13.7M 0.49%
127,100
– –
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$27.4B
$13.5M 0.48%
114,966
– –
MPT
42
Medical Properties Trust
MPT
$2.81B
$13.2M 0.47%
1,007,717
– –
ACHC icon
43
Acadia Healthcare
ACHC
$2.62B
$13M 0.47%
272,400
+41,200
+18% +$2.01M
WELL.PRI
44
DELISTED
Welltower Inc.
WELL.PRI
$12.7M 0.45%
200,000
– –
DHC
45
Diversified Healthcare Trust
DHC
$2.17B
$12.6M 0.45%
646,554
– –
PBYI icon
46
Puma Biotechnology
PBYI
$402M
$12.6M 0.45%
105,495
-97,042
-48% -$9.03M
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
$12.2M 0.44%
223,700
– –
SBRA icon
48
Sabra Healthcare REIT
SBRA
$5.38B
$12.1M 0.43%
550,990
– –
VTR icon
49
Ventas
VTR
$44.7B
$11.5M 0.41%
175,991
– –
DERM
50
DELISTED
Dermira, Inc.
DERM
$10.7M 0.38%
396,900
+10,000
+3% +$262K
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Tekla Capital Management held 164 positions worth $2.8B, up 3.6% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q3 2017 filing shows 19 new, 21 increased, 19 reduced and 11 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M. The largest sale was iShares Biotechnology ETF, an estimated $23.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M.
  • Tekla Capital Management added most to Gilead Sciences in Q3 2017, an estimated $20.7M increase.
  • Tekla Capital Management's biggest Q3 2017 reduction was Biogen, cutting an estimated $11.9M.
  • Tekla Capital Management fully exited iShares Biotechnology ETF in Q3 2017, selling an estimated $23.6M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.8B portfolio in Q3 2017.
  • Tekla Capital Management opened 19 new positions and closed 11 in Q3 2017.
  • Tekla Capital Management's portfolio value rose 3.6% quarter-over-quarter to $2.8B.

Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.